Incretin Effect in Women with Former Gestational Diabetes within a Short Period after Delivery

G Pacini, A Tura, Y Winhofer, A Kautzky-Willer, G Pacini, A Tura, Y Winhofer, A Kautzky-Willer

Abstract

Background and Aims. Women with former gestational diabetes (fGDM) are characterized by impaired beta-cell function (BC). Incretin hormones contribute to insulin secretion after oral administration of glucose. We aimed to assess the possible role of incretins on altered insulin release in fGDM. Materials and Methods. We studied 104 fGDM women within 6 months after delivery and 35 healthy women after normal pregnancy (CNT) with a 75 g oral (OGTT) and a 0.33 g/kg intravenous (IVGTT) glucose test, both lasting 3 h. The ratio of suprabasal areas under the concentration curves for glucose (dAUC(GL)) and C-peptide (dAUC(CP)) evaluated BC during OGTT (BC(OG)) and IVGTT (BC(IV)). Incretin effect was computed in all fGDM and in fGDM with normal tolerance (fGDM(NGT)) and with impaired glucose regulation (fGDM(IGR)). Results. dAUC(GL) of fGDM was higher (P < 0.0001) than CNT for both tests; while dAUC(CP) were not different. BC(OG) and BC(IV) were lower in fGDM versus CNT (1.42 ± 0.17nmol(CP)/mmol(GLUC) versus 2.53 ± 0.61, P = 0.015 and 0.41 ± 0.03 versus 0.68 ± 0.10, P = 0.0006, respectively). IE in CNT (66 ± 4 %) was not different from that of all fGDM (59 ± 3) and fGDM(NGT) (60 ± 3), but higher than that of fGDM(IGR) (52 ± 6; P = 0.03). IE normalized to BMI was 2.77 ± 0.19 % m(2)/kg in CNT, higher than that of fGDM(IGR) (1.75 ± 0.21; P = 0.02) and also of fGDM(NGT )(2.33 ± 0.11; P = 0.038). Conclusion. Compromised IE characterizes fGDM(IGR). In both fGDM categories, regardless their glucose tolerance, IE normalized to BMI was reduced, signifying an intrinsic characteristic of fGDM. Therefore, the diminished IE of fGDM seems to reflect an early abnormality of the general beta-cell dysfunction in the progression toward type 2 diabetes.

References

    1. Holst JJ. On the physiology of GIP and GLP-1. Hormone and Metabolic Research. 2004;36(11-12):747–754.
    1. Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. The Journal of Clinical Endocrinology & Metabolism. 1986;63(2):492–498.
    1. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29(1):46–52.
    1. Knop FK, Vilsbøll T, Højberg PV, et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes. 2007;56(8):1951–1959.
    1. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nature Reviews Endocrinology. 2009;5(5):262–269.
    1. Tura A, Mari A, Prikoszovich T, Pacini G, Kautzky-Willer A. Value of the intravenous and oral glucose tolerance tests for detecting subtle impairments in insulin sensitivity and beta-cell function in former gestational diabetes. Clinical Endocrinology. 2008;69(2):237–243.
    1. Tura A, Mari A, Winzer C, Kautzky-Willer A, Pacini G. Impaired β-cell function in lean normotolerant former gestational diabetic women. European Journal of Clinical Investigation. 2006;36(1):22–28.
    1. Pacini G, Tonolo G, Sambataro M, et al. Insulin sensitivity and glucose effectiveness: minimal model analysis of regular and insulin-modified FSIGT. American Journal of Physiology—Endocrinology and Metabolism. 1998;274(4):E592–E599.
    1. Musso G, Gambino R, Pacini G, De Michieli F, Cassader M. Prolonged saturated fat-induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver. American Journal of Clinical Nutrition. 2009;89(2):558–567.
    1. Knop FK, Aaboe K, Vilsbøll T, et al. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes, Obesity and Metabolism. In press.
    1. Meier JJ, Gallwitz B, Askenas M, et al. Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes. Diabetologia. 2005;48(9):1872–1881.
    1. Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and β-cell function. Best Practice & Research Clinical Endocrinology & Metabolism. 2003;17(3):305–322.
    1. Forbes S, Moonan M, Robinson S, et al. Impaired circulating glucagon-like peptide-1 response to oral glucose in women with previous gestational diabetes. Clinical Endocrinology. 2005;62(1):51–55.
    1. Vrbikova J, Hill M, Bendlova B, et al. Incretin levels in polycystic ovary syndrome. European Journal of Endocrinology. 2008;159(2):121–127.
    1. Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes. 2008;57(5):1340–1348.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere